Fed. Circ. Backs Teva In Cancer Drug IP Row With Generics
The Federal Circuit on Friday affirmed a district court ruling that Apotex and Mylan infringed patents on Teva's cancer drug Bendeka and failed to show the patents were invalid, a decision...To view the full article, register now.
Already a subscriber? Click here to view full article